Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival

Combination therapies against multiple targets are currently being developed to prevent resistance to a single chemotherapeutic agent and to extirpate pre-existing resistance in heterogeneous cancer cells in tumors due to selective pressure from the single agent. Gemcitabine (GEM), a chemotherapeuti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Des Devel Ther
Autors principals: Allison Logan, Stephanie, Brissenden, Amanda J, Szewczuk, Myron R, Neufeld, Ronald J
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546735/
https://ncbi.nlm.nih.gov/pubmed/28814832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S137934
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars